Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke

NCT03552354 PHASE4 COMPLETED

Intravenous thrombolysis is considered as the first choice for ischemic stroke. In the recent years, endovascular therapy is demonstrated to be effective to treat ischemic with big vessel occlusion. However, only a minority of patients can get intravenous thrombolysis or endovascular therapy due to the restricted time window and strict indications. Dual antiplatelet has been demonstrated to be effective in the patients with high risk of TIA or minor ischemic stroke (NIHSS\<4). But there is still stroke progression although dual antiplatelet. The ischemic stroke patients with NIHSS \> 3 has been recommended to give aspirin in most guidelines. Of those patients, mild to moderate stroke patients (3\<NIHSS\<10) will result in the poor outcomes if the progression occurs. In addition, large artery atherosclerosis (LAA) stroke is prone to progress. So, we argue that the mild to moderate stroke with LAA should be give more intensive antiplatelet. In the present study, argatroban combined with antiplatelet therapy (3-5 days) is used to treat the proposed patients to investigate the safety and effectiveness.

Details

Lead sponsor	General Hospital of Shenyang Military Region
Phase	PHASE4
Status	COMPLETED
Enrolment	120
Start date	Wed Oct 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Stroke, Ischemic

Interventions

• Argatroban plus dual antiplatelet

Countries

China